How should opsoclonus‑myoclonus‑ataxia syndrome be diagnosed and treated?

Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS)

Diagnose OMAS clinically based on the triad of chaotic saccadic eye movements (opsoclonus), myoclonus, and ataxia, then immediately initiate combined immunotherapy with corticosteroids plus intravenous immunoglobulin while simultaneously screening for neuroblastoma.

Diagnostic Approach

Clinical Recognition

OMAS presents with a characteristic triad that evolves over days to weeks 1:

• Opsoclonus: Chaotic, multidirectional saccadic eye movements (often initially misdiagnosed as nystagmus) 2
• Myoclonus: Stimulus-sensitive jerking movements
• Ataxia: Wide-based gait, truncal instability (most common initial symptom in 85.7% of cases) 2
• Behavioral changes: Irritability, sleep disturbances, developmental regression 3

Critical pitfall: Opsoclonus may not be present initially—ataxia and behavioral changes often precede it by weeks to months 2, 4. The median time to recognize opsoclonus in delayed diagnosis cases is 96 days versus 11.5 days in early diagnosis 5.

Mandatory Workup

Once OMAS is suspected, immediately pursue:

1. Neuroblastoma screening (present in 45-50% of pediatric cases) 6, 2:

   • CT chest/abdomen/pelvis or MRI
   • Urine catecholamines (VMA, HVA)
   • MIBG scan if initial imaging negative
   • Most tumors are <50mm, stage L1, located abdominally, thoracically, or sacrally 2

2. CSF analysis 6, 7:

   • Lymphocytic pleocytosis (present in only 25% of cases)
   • Elevated protein
   • Oligoclonal bands (may be present)
   • Antineuronal antibodies (typically negative—absence does not exclude diagnosis) 6

3. Exclude mimics: Infectious encephalitis, acute cerebellar ataxia, ADEM, toxic ingestions 7, 5

The diagnosis is clinical—no specific biomarker exists 1, 3. Do not delay treatment waiting for antibody results.

Treatment Algorithm

First-Line Therapy (Initiate Immediately)

Start combined immunotherapy at diagnosis 8, 6:

• Corticosteroids (high-dose methylprednisolone or oral prednisone)
• PLUS Intravenous immunoglobulin (IVIG)

Early combined therapy (within 1-2 months of onset) is associated with significantly lower cognitive impairment rates at 2 years compared to delayed or monotherapy 6. The evidence strongly supports multimodal regimens over single-agent therapy 8.

Tumor Management (If Present)

• Surgical resection of neuroblastoma is essential 6, 2
• Chemotherapy only if tumor characteristics require it 6
• Continue immunotherapy regardless of tumor treatment

Second-Line Therapy (For Relapses or Inadequate Response)

Add immunosuppressive agents 6, 2:

• Rituximab
• Cyclophosphamide
• Mycophenolate mofetil
• Azathioprine

Common pitfall: Relapses frequently occur when tapering corticosteroids 6. Taper slowly over many months while monitoring closely.

Age-Specific Considerations

Pediatric OMAS (Most Common)

• Peak age: 18-36 months 2
• 45-50% paraneoplastic (neuroblastoma) 6, 2
• Higher risk of long-term cognitive sequelae despite treatment 1
• Requires aggressive early immunotherapy 8

Adult OMAS

• Idiopathic form: More common in younger women, monophasic course, excellent response to IVIG or corticosteroids 1
• Paraneoplastic form: Older women, associated with breast cancer or SCLC 1

Prognosis and Monitoring

After median follow-up of 40 months, approximately 60% of children have no neurological sequelae, while 40% have mild-to-moderate cognitive impairment 2. Early immunotherapy initiation (within 1.1 months of onset) and triple combination therapy are the strongest predictors of favorable cognitive outcomes 6.

Long-term follow-up is mandatory as developmental delays may emerge years later despite initial symptom resolution 1.